0000950170-24-003372.txt : 20240109
0000950170-24-003372.hdr.sgml : 20240109
20240109163419
ACCESSION NUMBER: 0000950170-24-003372
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240108
FILED AS OF DATE: 20240109
DATE AS OF CHANGE: 20240109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brannan Stephen K.
CENTRAL INDEX KEY: 0001777631
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 24523677
MAIL ADDRESS:
STREET 1: C/O KARUNA THERAPEUTICS, INC.
STREET 2: 33 ARCH STREET, SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 99 HIGH STREET
STREET 2: 26TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
ownership.xml
4
X0508
4
2024-01-08
false
0001771917
Karuna Therapeutics, Inc.
KRTX
0001777631
Brannan Stephen K.
C/O KARUNA THERAPEUTICS, INC.
99 HIGH STREET, 26TH FLOOR
BOSTON
MA
02110
false
true
false
false
Chief Medical Officer
true
Common Stock
2024-01-08
4
M
false
2500
5.45
A
38650
D
Common Stock
2024-01-08
4
M
false
5304
131.64
A
43954
D
Common Stock
2024-01-08
4
M
false
9696
111.97
A
53650
D
Common Stock
2024-01-08
4
S
false
15000
316.81
D
38650
D
Option (right to buy)
5.45
2024-01-08
4
M
false
2500
0
D
2027-06-01
Common Stock
2500
9677
D
Option (right to buy)
131.64
2024-01-08
4
M
false
5304
0
D
2031-02-22
Common Stock
5304
16046
D
Option (right to buy)
111.97
2024-01-08
4
M
false
9696
0
D
2032-02-16
Common Stock
9696
44604
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.47 to $317.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 23, 2021, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 16, 2022, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter.
/s/ Mia Kelley, Attorney-in-Fact
2024-01-09